NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 420
(Total Views: 156)
Posted On: 07/27/2022 3:38:37 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorizations.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorizations.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼